Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen D Ryder

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Journal of Hepatology|June 14, 2019
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysisSergio M Borgia, Janet Dearden, Eric M Yoshida, et al.
BMJ (Clinical Research Ed.)|August 2, 2023
Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort studyVictoria Hamill, Stanley Wong, Jennifer Benselin, et al.
Hepatology (Baltimore, Md.)|June 30, 2023
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled studyGideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, et al.
Journal of Hepatology|April 8, 2023
Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countriesHomie A Razavi, Maria Buti, Norah A Terrault, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Journal of Hepatology|June 14, 2019
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysisSergio M Borgia, Janet Dearden, Eric M Yoshida, et al.
BMJ (Clinical Research Ed.)|August 2, 2023
Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort studyVictoria Hamill, Stanley Wong, Jennifer Benselin, et al.
Hepatology (Baltimore, Md.)|June 30, 2023
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled studyGideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, et al.
Journal of Hepatology|April 8, 2023
Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countriesHomie A Razavi, Maria Buti, Norah A Terrault, et al.
Pageof 8